Search research articles
Contact Us
Filters
Showing results (251-260 of 426) with videos related to
Page
of 43
Sort By:
European Urology
|
March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
Johann S de Bono, Mark T Fleming, Judy S Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies
Chooi P Lee, Maja J A de Jonge, Anne E O'Donnell, et al.
NPJ Precision Oncology
|
November 26, 2025
Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer
Sara Arce-Gallego, Victor Esquefa, Heura Domenech, et al.
Eclinicalmedicine
|
October 21, 2024
Multivariable models of outcomes with [<sup>177</sup>Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
Ken Herrmann, Andrei Gafita, Johann S de Bono, et al.
BJU International
|
August 20, 2016
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer
Andrew S McDaniel, Roberta Ferraldeschi, Rachel Krupa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2017
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit
Dionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2018
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Daniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 20, 2018
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials
Raghav Sundar, Terri McVeigh, David Dolling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, H-T Arkenau, J E Ang, et al.
Page
of 43
Search research articles
Search
Showing results (251-260 of 426) with videos related to
Sort By:
Page
of 43
European Urology
|
March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
Johann S de Bono, Mark T Fleming, Judy S Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies
Chooi P Lee, Maja J A de Jonge, Anne E O'Donnell, et al.
NPJ Precision Oncology
|
November 26, 2025
Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer
Sara Arce-Gallego, Victor Esquefa, Heura Domenech, et al.
Eclinicalmedicine
|
October 21, 2024
Multivariable models of outcomes with [<sup>177</sup>Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
Ken Herrmann, Andrei Gafita, Johann S de Bono, et al.
BJU International
|
August 20, 2016
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer
Andrew S McDaniel, Roberta Ferraldeschi, Rachel Krupa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2017
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit
Dionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2018
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Daniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 20, 2018
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials
Raghav Sundar, Terri McVeigh, David Dolling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, H-T Arkenau, J E Ang, et al.
Page
of 43